4/A: Johnson & Johnson Amends CVRx Stock Sale Disclosure

Johnson & Johnson's subsidiary, JJDC, amended its Form 4 filing to disclose additional sales of CVRx, Inc. common stock totaling 22,337 shares in late 2025.

Summary

• Johnson & Johnson, through its wholly-owned subsidiary Johnson & Johnson Innovation JJDC, Inc. (JJDC), filed an amendment to its Form 4.
• The amendment corrects an administrative oversight, including a previously omitted sale of 16,000 shares of CVRx, Inc. common stock on November 25, 2025.
• JJDC also reported the sale of 6,337 shares of CVRx, Inc. common stock on November 26, 2025.
• Both sales were executed at a weighted average price of $10.03 per share.
• Following these transactions, JJDC's indirect beneficial ownership in CVRx, Inc. stands at 4,024,861 shares.

Sentiment

Score: 3

Explanation: The filing reports significant insider selling by a major shareholder and an administrative error in reporting, which are generally viewed negatively by the market.

Negatives

• Johnson & Johnson's subsidiary, JJDC, sold a total of 22,337 shares of CVRx, Inc. common stock.
• The sales occurred at a weighted average price of $10.03 per share.
• An administrative oversight led to the omission of a significant transaction (16,000 shares) from the original filing, requiring an amendment.

Future Outlook

NA

Industry Context

This filing details an insider transaction by a major institutional investor, Johnson & Johnson, through its subsidiary JJDC, in CVRx, Inc. Such transactions are typically viewed in the context of the specific company's performance and the broader market sentiment for medical device or healthcare technology companies, rather than reflecting general industry trends.

Stakeholder Impact

• Shareholders of CVRx, Inc. may interpret the insider selling by a major shareholder (Johnson & Johnson/JJDC) as a negative signal regarding the company's future prospects or valuation.
• Johnson & Johnson Shareholders: The sale represents a divestment from a portfolio company, potentially freeing up capital for other investments or strategic priorities.

Next Steps

• The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the reported ranges.

Key Dates

Recommendation

The sale of a significant number of shares by a major institutional investor like Johnson & Johnson (through JJDC), especially when it represents a reduction in their stake, often signals a lack of confidence in the near-term prospects or valuation of CVRx, Inc. This insider selling, coupled with the administrative oversight requiring an amendment, suggests a cautious stance. Investors might interpret this as a signal to reduce exposure or avoid the stock.

Keywords

CVRx Inc, CVRX, Johnson & Johnson, JJDC, Form 4/A, Insider Selling, Stock Sale, Beneficial Ownership, SEC Filing